Gutiérrez, Lourdes
Royuela, Ana
Carcereny, Enric
López-Castro, Rafael
Rodríguez-Abreu, Delvys
Massuti, Bartomeu
González-Larriba, José Luis
García-Campelo, Rosario
Bosch-Barrera, Joaquim
Guirado, María
Camps, Carlos
Dómine, Manuel
Bernabé, Reyes
Casal, Joaquín
Oramas, Juana
Ortega, Ana Laura
Sala, Mª. Angeles
Padilla, Airam
Aguiar, David
Juan-Vidal, Oscar
Blanco, Remei
del Barco, Edel
Martínez-Banaclocha, Natividad
Benítez, Gretel
de Vega, Blanca
Hernández, Ainhoa
Saigi, Maria
Franco, Fernando
Provencio, Mariano
Article History
Received: 14 April 2021
Accepted: 16 August 2021
First Online: 31 August 2021
Declarations
:
: This study used data from the Thoracic Tumor Registry (TTR) managed by the Spanish Lung Cancer Group (SLCG).The registry was approved in 2016 by the Spanish Agency for Medicines and Medical Devices (AEMPS) and is registered on the ExternalRef removed database (ExternalRef removed). The TTR is an observational study (patient registry) of prospectively and retrospectively collected patient information.The protocol approval was obtained from the institutional review board of the Puerta de Hierro University Teaching Hospital (Majadahonda, Madrid) (no. PI 148/15). The requirement for informed consent was exempted by the ethics institutional review board of the Puerta de Hierro University Hospital (Majadahonda, Madrid). The data is de-identified and holds no identifying patient information, and therefore, written informed consent was not needed for this study.The study was carried out in accordance with the Helsinki Declaration.
: Not applicable.
: The authors LG, EC, RLC, DRA, BM, JLGL, MG, CC, MD, RB, JC, JO, ALO, MAS, AP, DA, RB, EB, NM, GB, BV, AH, MS, FF, AR have no conflict of interest to declare in relation to this study.RGC reports honoraria, speaker’s bureau, consultant fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Novartis, Janssen and Takeda, Roche.JBB reports grants and personal fees from Roche-Genentech and Pfizer; personal fees from MSD, BMS, Astrazeneca, Novartis, and Boehringer-Ingelheim.OJV reports honoraria from Bristol-Myers Squibb, Roche/Genentech, MSD Oncology, AstraZeneca/MedImmune. Consulting or Advisory Role from Boehringer Ingelheim, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, Lilly, Takeda. Speakers’ Bureau from Roche/Genentech. Travel, Accommodations, Expenses from Roche/Genentech, Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb.MP reports grants from BMS, Roche, AstraZeneca and personal fees from BMS, Roche, AstraZeneca, MSD, Takeda. Non-financial support from BMS, Roche, AstraZeneca.